Based on the Inozyme Pharma Inc stock forecast from 2 analysts, the average analyst target price for Inozyme Pharma Inc is USD 12.20 over the next 12 months. Inozyme Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Inozyme Pharma Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Inozyme Pharma Inc’s stock price was USD 1.08. Inozyme Pharma Inc’s stock price has changed by -9.24% over the past week, -20.00% over the past month and -81.28% over the last year.
No recent analyst target price found for Inozyme Pharma Inc
No recent average analyst rating found for Inozyme Pharma Inc
Company Overview Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read Less
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engin...Read More
Frequently Asked Questions About Inozyme Pharma Inc (INZY) Stock
Based on ratings from 2 analysts Inozyme Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on INZY's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INZY is USD 12.20 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on INZY's stock to indicate if its overvalued.
The last closing price of INZY's stock was USD 1.08.
The most recent market capitalization for INZY is USD 0.07B.
Based on targets from 2 analysts, the average taret price for INZY is projected at USD 12.20 over the next 12 months.
This means that INZY's stock price may go up by +1,029.63% over the next 12 months.
We can't find any ETFs which contains Inozyme Pharma Inc's stock.
As per our most recent records Inozyme Pharma Inc has 59 Employees.
Inozyme Pharma Inc's registered address is 321 Summer Street, Boston, MA, United States, 02210.
You can get more information about it from Inozyme Pharma Inc's website at https://www.inozyme.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Inozyme Pharma Inc (INZY) Stock
Based on ratings from 2 analysts Inozyme Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on INZY's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INZY is USD 12.20 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on INZY's stock to indicate if its overvalued.
The last closing price of INZY's stock was USD 1.08.
The most recent market capitalization for INZY is USD 0.07B.
Based on targets from 2 analysts, the average taret price for INZY is projected at USD 12.20 over the next 12 months.
This means that INZY's stock price may go up by +1,029.63% over the next 12 months.
We can't find any ETFs which contains Inozyme Pharma Inc's stock.
As per our most recent records Inozyme Pharma Inc has 59 Employees.
Inozyme Pharma Inc's registered address is 321 Summer Street, Boston, MA, United States, 02210.
You can get more information about it from Inozyme Pharma Inc's website at https://www.inozyme.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INZY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
